These findings suggest a fluctuating yet stronger involvement of the immune–inflammatory response system in BD patients than in MDD patients and the possibility that modulation of active markers such as CRP could modify or support therapeutic interventions in MDD [80,81,82]. Here, CRP is linked to Behcet disease.